Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

7.8K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.8K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

668
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
668

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fall Risk and Fear of Falling Among Older Adults in Cardiac Rehabilitation: ARTICULATING RISK FACTORS, PREVALENCE, PATIENT CHARACTERISTICS, AND OUTCOMES.

Journal of cardiopulmonary rehabilitation and prevention·2026
Same author

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Interchangeability of CSF and PET to identify Alzheimer's disease pathology.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Treatment of Clinically Diagnosed Alzheimer's Disease by External Counterpulsation A Randomized Clinical Trial.

American journal of Alzheimer's disease and other dementias·2026
Same author

Racial Disparities in Biopsychosocial Predictors of Short-Term Smoking Cessation Following Acute Coronary Syndrome Hospitalization.

Journal of racial and ethnic health disparities·2026
Same author

Interchangeability of blood-based biomarkers and PET to identify Alzheimer's disease pathology.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Related Experiment Video

Updated: Feb 26, 2026

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat
15:10

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

Published on: December 28, 2013

7.4K

Correlation between two methods of florbetapir PET quantitative analysis.

Christopher Breault1,2, Jonathan Piper3, Abhinay D Joshi1

  • 1Avid Radiopharmaceuticals (A Wholly Owned Subsidiary of Eli Lilly and Company)3711 Market St, Philadelphia 19104, PA, U S A.

American Journal of Nuclear Medicine and Molecular Imaging
|July 20, 2017
PubMed
Summary

A new commercial software for florbetapir PET analysis shows comparable results to the established research method for calculating standard uptake value ratios (SUVr). This validates its use for quantitative amyloid imaging in Alzheimer's disease diagnosis.

Keywords:
Amyloid imagingPET quantitationamyloid PETamyvidflorbetapir

More Related Videos

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level
07:28

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

737
Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

11.0K

Related Experiment Videos

Last Updated: Feb 26, 2026

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat
15:10

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

Published on: December 28, 2013

7.4K
Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level
07:28

Studying Metabolic Brain Connectivity Using 2-Deoxy-2-[18F]Fluoro-D-Glucose Dynamic Positron Emission Tomography at the Single-subject Level

Published on: January 24, 2025

737
Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

11.0K

Area of Science:

  • Nuclear Medicine
  • Neuroimaging
  • Biomarker Quantification

Background:

  • Alzheimer's disease (AD) diagnosis relies on accurate amyloid-beta (Aβ) detection.
  • Florbetapir positron emission tomography (PET) is a key imaging modality for Aβ detection.
  • Standardized quantification of florbetapir PET data is crucial for clinical translation.

Purpose of the Study:

  • To evaluate the performance of a commercial software for florbetapir PET standard uptake value ratio (SUVr) calculation.
  • To compare the commercial software's SUVr results against an established research-based method.
  • To assess the clinical utility of standardized SUVr analysis in Alzheimer's disease diagnostics.

Main Methods:

  • 183 subjects (cognitively normal, mild cognitive impairment, probable AD) underwent florbetapir PET imaging.
  • SUVr was calculated using both a commercial software and a research method.
  • Cortical SUVr values were computed across six regions using the cerebellum as a reference.

Main Results:

  • SUVr values from the commercial and research methods showed a strong correlation (r² = 0.98).
  • The regression equation was: Commercial SUVr = (0.9757 * Research SUVr) + 0.0299.
  • The established cutoff of 1.1 for amyloid positivity was consistent between both methods.

Conclusions:

  • The commercial software provides comparable SUVr quantification to the research method for florbetapir PET.
  • This commercial tool facilitates the adoption of standardized quantitative approaches in PET amyloid imaging.
  • The findings support the use of commercial software for reliable Alzheimer's disease biomarker assessment.